Amoxicillin + clavulanic acid

Statut de médicament

Description générale

Amoxicillin is an extended spectrum penicillin antibiotic. Clavulanic acid is a beta-lactamase inhibitor.

INN	Amoxicillin + clavulanic acid
Codes ATC	J01CR02
Type de médicament	Chemical agent
Groupes d'antibiotiques	A ACCESS
Historique des statuts LME	Ajouté pour la première fois en 1997 (TRS 882) pour Bacterial infection of unspecified site Ajouté en 2017 (TRS 1006) pour Acute otitis media Ajouté en 2017 (TRS 1006) pour Infectious cystitis Ajouté en 2017 (TRS 1006) pour Chronic obstructive pulmonary disease with acute exacerbation Ajouté en 2017 (TRS 1006) pour Acute sinusitis Ajouté en 2017 (TRS 1006) pour Bacterial cellulitis, erysipelas or lymphangitis Ajouté en 2017 (TRS 1006) pour Osteomyelitis or osteitis Ajouté en 2017 (TRS 1006) pour Bacterial infection of joint Retiré en 2017 (TRS 1006) pour Bacterial infection of unspecified site Ajouté en 2017 (TRS 1006) pour Neutropaenia Ajouté en 2017 (TRS 1006) pour Peritoneal abscess Ajouté en 2017 (TRS 1006) pour Peritonitis Ajouté en 2017 (TRS 1006) pour Bacterial pneumonia Ajouté en 2017 (TRS 1006) pour Other specified pneumonia Ajouté en 2019 (TRS 1021) pour Other specified prophylactic measures Ajouté en 2019 (TRS 1021) pour Multi-drug resistant Mycobacterium tuberculosis
Wikipédia	Amoxicillin + clavulanic acid
DrugBank	Amoxicillin, Clavulanic acid (Clavulanate)

Recommandations

Section Access group antibiotics

- Parenteral > General injections > IV: 500 mg (as sodium salt) + 100 mg (as potassium salt) powder for injection 1000 mg (as sodium salt) + 200 mg (as potassium salt) powder for injection
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)
- Oral > Liquid: 125 mg (as trihydrate) + 31.25 mg (as potassium salt) / 5 mL powder for oral liquid; 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
- Oral > Solid > dispersible tablet: 200 mg (as trihydrate) + 28.5 mg (as potassium salt); 250 mg (as trihydrate) + 62.5 mg (as potassium salt)
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt); 875 mg (as trihydrate) + 125 mg (as potassium salt)

Indications

Premier choix

Chronic obstructive pulmonary disease with acute exacerbation

Infectious cystitis

Acute sinusitis

Bacterial cellulitis, erysipelas or lymphangitis

Neutropaenia (low-risk)

Peritoneal abscess (mild-moderate)

Peritonitis (mild-moderate)

Bacterial pneumonia (Community-acquired pneumonia - severe) [children]

Other specified pneumonia (Hospital-acquired pneumonia)

Second choix

Osteomyelitis or osteitis

Bacterial infection of joint

Acute otitis media

Bacterial pneumonia (Community-acquired pneumonia - mild to moderate)

Bacterial pneumonia (Community-acquired pneumonia - severe)

Other specified prophylactic measures

Autres indications

Bacterial infection of unspecified site

Section Antituberculosis medicines

- Oral > Liquid: 250 mg (as trihydrate) + 62.5 mg (as potassium salt) / 5 mL powder for oral liquid
- Oral > Solid > dispersible tablet: 250 (as trihydrate) + 62.5 (as potassium salt)
- Oral > Solid > tablet: 500 mg (as trihydrate) + 125 mg (as potassium salt)

Indications

Multi-drug resistant Mycobacterium tuberculosis